Evaluation of the Diagnostic Potential a Lateral Flow Assay to Detect QSOX1 Peptide in Patients in Patients with or At Risk for Pancreatic Cancer Evaluation of the Diagnostic Potential a Lateral Flow Assay to Detect QSOX1 Peptide in Patients in Patients with or At Risk for Pancreatic Cancer Lake laboratory will process blood into serum from 20 patients with established pancreas cancer and 20 patients with benign pancreas disorders. Cyst fluid will provided by Dr. Faigel (Mayo) from patients undergoing EUS. Lake lab will process the cyst fluid Lateral flow assays (LFAs) that detect QSOX1 will be assembled using antibodies produced, purified and quantified in the Lake lab. All sera and cyst fluid will be run in the LFAs to determine concentrations of QSOX1 in each patients biofluid. Drs. Lake and Faigel will compare levels of QSOX1 with CEA and CA19.9 for each patient in sera and cyst fluid.
|Effective start/end date||6/1/19 → 6/1/20|
- Mayo Clinic Arizona: $25,000.00
Explore the research topics touched on by this project. These labels are generated based on the underlying awards/grants. Together they form a unique fingerprint.